List view / Grid view
Agreement is ViiV Healthcare’s first external collaboration for development of…
12 June 2014 | By GlaxoSmithKline
Agreement is ViiV Healthcare’s first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine...
ViiV Healthcare is pleased to announce that the U.S. FDA…
ViiV Healthcare is pleased to announce that the U.S. FDA has approved Tivicay® (dolutegravir) 50-mg tablets...
ViiV Healthcare Ltd and Shionogi & Co., Ltd., have entered…
29 October 2012 | By GlaxoSmithKline
ViiV Healthcare Ltd and Shionogi & Co., Ltd., have entered into an agreement...
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir...
2 April 2012 | By GlaxoSmithKline
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir...
